Trial Profile
Anamorelin HCl in the Treatment of Non-Small Cell Lung Cancer-Cachexia (NSCLC-C): A Randomized Double-Blind Placebo-Controlled Multicenter Phase III Study to Evaluate the Safety and Efficacy of Anamorelin HCl in Patients With NSCLC-C
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2018
Price :
$35
*
At a glance
- Drugs Anamorelin (Primary)
- Indications Anorexia; Cachexia
- Focus Registrational; Therapeutic Use
- Acronyms ROMANA-1
- Sponsors Helsinn Therapeutics
- 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 assessing the baseline characteristics of patients with mGPS 0-2 presented at the 42nd European Society for Medical Oncology Congress
- 12 Sep 2017 Results (n=829) of pooled post hoc analysis of NCT01387269 and NCT01387282 trials assessing efficacy of anamorelin in cachectic non small cell lung cancer patients with modified Glasgow Prognostic Score 2 (C-reactive protein levels more than 10mg/L and albumin levels less than 3.5g/dL) presented at the 42nd European Society for Medical Oncology Congress
- 02 Jun 2017 Results of post-hoc pooled analysis (n=829) of two pivotal trials (ROMANA 1 and ROMANA 2) assessing the body weight response with anamorelin, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.